目的 通过对用丹参多酚酸联合依达拉奉治疗急性脑梗死的疗效进行分析，同时观察治疗对血液流变学的影响，从而判断两种药物联合治疗对于治疗急性脑梗死的临床价值。方法 将2016年1月—2018年12月在安阳市第六人民医院院神经内科接受诊治的80例脑梗死患者使用随机数表法对进行分组，对照组、治疗组各40例。对照组患者在常规治疗基础上使用依达拉奉注射液，治疗组在对照组治疗基础上加用注射用丹参多酚酸0.13 g溶于0.9%氯化钠注射液250 mL中静脉滴注，1次/d。两组经过14 d的治疗后，对比患者的治疗效果、对治疗前后血液流变学相关指标的影响以及NIHSS评分改善状况。结果 治疗前两组的NIHSS评分比较无统计学差异；治疗后，两组NIHSS评分均降低，且治疗组的低于对照组，两组比较差异具有显著性（P<0.05）。治疗后，对照组的总有效率为52.5%，治疗组的总有效率为85.0%，且治疗组的总有效率高于对照组，两组比较差异具有显著性（P<0.05）。在治疗前，两组患者的血浆黏度、纤维蛋白原、红细胞压积无显著性差异。治疗后，两组患者的血浆黏度、纤维蛋白原、红细胞压积均降低，且治疗组的低于对照组的，差异具有显著性（P<0.05）。结论 注射用丹参多酚酸盐联合依达拉奉治疗急性脑梗死与单一使用依达拉奉相比，近期疗效确切同时改善患者的血液流变学指标，降低患者NIHSS评分。

Objective This study analyzed the efficacy of Salvianolic Acids for Injection combined with Edaravone in the treatment of acute cerebral infarction, and observed the effect of treatment on hemorheology, so as to judge the clinical value of the combination of two drugs for the treatment of acute cerebral infarction. Methods Eighty patients with cerebral infarction who were treated in our department of neurology from January 2016 to December 2018 were included in the study. Patients were grouped using a random number table method, with 40 patients in the control group. In the control group, edaravone injection was used on the basis of conventional treatment, and the experimental group was supplemented with Salvianolic Acids for Injection. After a course of treatment for 14 days, the effects of the two groups of patients, the effects of blood rheology related indicators before and after treatment, and the improvement of NIHSS scores were compared. Results The NIHSS scores of the two groups were not significantly different before treatment. After two weeks of treatment, the NIHSS score of the experimental group was lower than that of the control group, and the difference was significant (P<0.05). After two weeks of treatment, the total effective rate of the experimental group was higher than that of the control group, and the difference was significant (P<0.05). There were no significant differences in plasma viscosity, fibrinogen, and hematocrit between the two groups before treatment. After two weeks of treatment, the plasma viscosity, fibrinogen, and hematocrit of the experimental group were lower than those of the control group, and the difference was significant (P<0.05). Conclusion Intravenous salvianolate combined with edaravone in the treatment of acute cerebral infarction compared with single use of edaravone, the short-term efficacy of the immediate improvement of the patient's blood rheology indicators, reduce the patient's NIHSS score.

R969.4